In today’s briefing:
- Clinuvel Pharmaceuticals (CUV AU): A Profitable Growth Story, With Sustainable Long-Term Future
Clinuvel Pharmaceuticals (CUV AU): A Profitable Growth Story, With Sustainable Long-Term Future
- Clinuvel Pharmaceuticals (CUV AU) has sole marketed drug, Scenesse, approved in the U.S. and Europe for the treatment of a rare skin disorder that causes extreme sensitivity to light.
- Scenesse revenue jumped 65% y/y in H1FY22, due to increasing patient demand. With the re-opening of expert centers, treatment has largely normalized in Europe.
- Clinuvel has rich pipeline, to develop pharmaceutical products to treat a range of indications and non-prescription healthcare solutions to individuals in the wider population.
Before it’s here, it’s on Smartkarma
